Outcome of Relapsed or Refractory
FLT3-ITD mutation
FLT3-TKD mutation
acute myeloid leukemia
gilteritinib
primary induction failure
refractory
relapse
tyrosine kinase inhibitors
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Mar 2020
25 Mar 2020
Historique:
received:
04
03
2020
revised:
21
03
2020
accepted:
22
03
2020
entrez:
29
3
2020
pubmed:
29
3
2020
medline:
29
3
2020
Statut:
epublish
Résumé
A recent phase 3 trial showed that the outcome of patients with relapsed/refractory (R/R)
Identifiants
pubmed: 32218221
pii: cancers12040773
doi: 10.3390/cancers12040773
pmc: PMC7226007
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Leukemia. 2011 Jun;25(6):939-44
pubmed: 21331073
Blood Cancer J. 2017 Nov 29;7(12):635
pubmed: 29184070
Leukemia. 1996 Dec;10(12):1911-8
pubmed: 8946930
Nature. 2012 Apr 15;485(7397):260-3
pubmed: 22504184
Ann Intern Med. 1993 Feb 1;118(3):201-10
pubmed: 8417638
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Leukemia. 1997 Sep;11(9):1447-52
pubmed: 9305596
N Engl J Med. 2019 Oct 31;381(18):1728-1740
pubmed: 31665578
J Clin Oncol. 2005 Mar 20;23(9):1969-78
pubmed: 15632409
Ann Hematol. 2018 Jul;97(7):1115-1153
pubmed: 29680875
Blood. 1998 Oct 1;92(7):2322-33
pubmed: 9746770
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Leukemia. 2015 Jul;29(7):1470-7
pubmed: 25976987
Lancet Oncol. 2019 Jul;20(7):984-997
pubmed: 31175001
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
N Engl J Med. 2017 Aug 3;377(5):454-464
pubmed: 28644114
Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):459-63
pubmed: 7507245